# A Clinical Trial of TQB3909 Tablets in Patients With Breast Cancer

> **NCT05775575** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Chia Tai Tianqing Pharmaceutical Group Co., Ltd.** · enrollment: 65 (estimated)

## Conditions studied

- Advanced Breast Cancer

## Interventions

- **DRUG:** TQB3909 tablets

## Key facts

- **NCT ID:** NCT05775575
- **Lead sponsor:** Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-03-02
- **Primary completion:** 2023-12
- **Final completion:** 2023-12
- **Target enrollment:** 65 (ESTIMATED)
- **Last updated:** 2023-03-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05775575

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05775575, "A Clinical Trial of TQB3909 Tablets in Patients With Breast Cancer". Retrieved via AI Analytics 2026-06-11 from https://api.ai-analytics.org/clinical/NCT05775575. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*